Key Highlights:

• PainChek shares rose 15.00% to AUD 0.12.

• The stock traded between AUD 0.11 and AUD 0.12 during the session.

• Shares remain well below the 52-week high of AUD 1.05 but above the 52-week low of AUD 0.09.

• Investors continue monitoring commercial adoption, customer growth and healthcare technology expansion.

PainChek Ltd (ASX: PCK) attracted renewed buying interest on 7 July, with its shares climbing 15.00% to close at AUD 0.12. The stock traded between AUD 0.11 and AUD 0.12 during the session, finishing at the day's high.

Although the shares remain well below their 52-week high of AUD 1.05, today's move suggests improving investor sentiment towards healthcare technology companies focused on digital innovation.

Why Did PainChek Rally?

The strong share price gain appears to reflect renewed interest in healthcare technology stocks, particularly companies developing digital solutions that improve patient care and clinical outcomes.

Small-cap healthcare companies often experience significant price movements when investors anticipate stronger commercial traction or broader adoption of their technology platforms.

Today's rally indicates growing optimism surrounding PainChek's long-term growth potential.

Digital Pain Assessment Remains the Core Business

PainChek develops artificial intelligence-based pain assessment technology designed to help healthcare professionals identify and monitor pain, particularly in individuals who cannot effectively communicate their symptoms.

Its technology is used across aged care, hospitals and healthcare settings to support clinical decision-making and improve patient care.

Continued customer adoption remains a key growth driver.

Healthcare Technology Continues to Gain Attention

Digital health solutions continue to attract investment as healthcare providers increasingly adopt technologies that improve efficiency, patient outcomes and clinical workflows.

Companies offering scalable software platforms and AI-enabled healthcare tools are well positioned to benefit from ongoing digital transformation across the healthcare sector.

Investors remain focused on commercial execution and customer expansion.

Recovery Still Has Room to Build

Despite today's gain, PainChek shares remain significantly below their 52-week high.

Future performance will likely depend on increasing customer adoption, expanding recurring revenue, international growth opportunities and continued product development.

Operational updates could provide further catalysts for the stock.

What Could Investors Watch Next?

Several developments may influence PainChek's future performance:

• New customer wins and contract announcements.

• Growth in recurring revenue.

• International expansion.

• Product enhancements and technology development.

• Strategic healthcare partnerships.

• Financial and operational updates.

Positive execution across these areas could strengthen investor confidence.

Risks to Consider

PainChek remains exposed to customer adoption risk, competitive pressures, regulatory requirements and execution challenges associated with scaling healthcare technology businesses.

As a small-cap healthcare company, its share price may continue experiencing elevated volatility.

Outlook

PainChek gained 15% as investors returned to selected healthcare technology stocks. While the shares remain well below their annual high, continued growth in customer adoption, commercial execution and expansion into new healthcare markets could support future momentum. Investors are expected to monitor operational updates and commercial progress closely.